Spiich Labs Raises €3M Seed to Advance AI Voice Biomarker Diagnostics

Spiich Labs Secures €3M Seed Round

Stockholm-based Spiich Labs has raised €3 million in Seed funding, according to a funding announcement dated September 23, 2026. The round was led by Ugly Duckling Ventures, with participation from Alliance VC, Ampli Ventures, and Cherry Ventures.

What Spiich Labs Does

Spiich Labs is developing AI-powered speech analysis technology for healthcare diagnostics. The company focuses on voice biomarkers as a means to detect neurological and respiratory conditions. Its approach emphasizes privacy-preserving methods designed to comply with European regulations.

The combination of voice-based diagnostics and privacy-first data handling positions Spiich Labs at the intersection of two growing areas in European health technology: non-invasive screening tools and regulatory-compliant data processing.

Funding Details

• Round type: Seed
• Amount: €3,000,000
• Currency: EUR
• Announced date: September 23, 2026
• Lead investor: Ugly Duckling Ventures
• Participating investors: Alliance VC, Ampli Ventures, Cherry Ventures

Why This Round Matters

Seed funding at this scale gives Spiich Labs capital to continue developing its speech analysis platform and voice biomarker technology. The involvement of multiple venture firms — including a designated lead — signals investor confidence in the company's technical direction and its focus on European regulatory compliance.

For observers tracking AI in healthcare, Spiich Labs represents a segment where software-driven diagnostics can potentially reduce reliance on more invasive or resource-intensive testing methods. Voice biomarkers, if validated, could offer scalable screening pathways for neurological and respiratory conditions.

Acquisition and Partnership Angle

The Seed round establishes Spiich Labs as an early-stage company with institutional backing. Its Stockholm base and European regulatory focus make it relevant to healthcare systems operating under GDPR and related frameworks. Strategic acquirers in diagnostics, digital health, and clinical AI may view voice biomarker platforms as complementary to existing screening or monitoring portfolios.

At this stage, the company's priorities are likely centered on technology development and validation. The participation of four named investors provides both capital and network access as Spiich Labs builds out its platform.

Summary

Spiich Labs has closed a €3 million Seed round led by Ugly Duckling Ventures, with Alliance VC, Ampli Ventures, and Cherry Ventures also participating. The Stockholm startup is developing AI-powered speech analysis for healthcare diagnostics, using voice biomarkers to detect neurological and respiratory conditions with privacy-preserving methods compliant with European regulations. The funding was announced on September 23, 2026.